Lei L. Chen

SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions

Lei L. Chen, Jing Zhu, Jonathan A. Schumacher, Chongjuan Wei et autres

We demonstrate that SCF-KIT signaling induces synthesis and secretion of endothelin-3 (ET3) in human umbilical vein endothelial cells and melanoma cells in vitro, gastrointestinal stromal tumors, human sun-exposed skin, and myenteric plexus of human colon post-fasting in vivo. This is the first …

us, cn (code pays fourni par la source)

Exploiting anti-tumor immunity to overcome relapse and improve remission duration

Lei L. Chen

Cancer survivors often relapse due to evolving drug-resistant clones and repopulating tumor stem cells. Our preclinical study demonstrated that terminal cancer patient's lymphocytes can be converted from tolerant bystanders in vivo into effective cytotoxic T-lymphocytes in vitro killing patient's own tumor cells …

Combining targeted therapy with immunotherapy (interferon-α)

Lei L. Chen, Launce Gouw, Mahyar Sabripour, Wen-Jen Hwu et autres

Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAF(V600)-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and …

us, au (code pays fourni par la source)

Exploiting antitumor immunity to overcome relapse and improve remission duration

Lei L. Chen, Xinjian Chen, Hongxun Sang, Hongbo Zhang et autres

Cancer survivors often relapse due to evolving drug-resistant clones and repopulating tumor stem cells. Our preclinical study demonstrated that terminal cancer patient's lymphocytes can be converted from tolerant bystanders in vivo into effective cytotoxic T-lymphocytes in vitro killing patient's own tumor cells …

us, cn (code pays fourni par la source)

Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression

Lei L. Chen, Joseph A. Holden, Haesun Choi, Jing Zhu et autres

us (code pays fourni par la source)

Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor

Eric P. Kleinbaum, Alexander J. Lazar, Elena Tamborini, John C. McAuliffe et autres

Germ-line mutations in the KIT receptor tyrosine kinase gene have been described in families with a propensity to develop gastrointestinal stromal tumor (GIST). There is limited information from large kindreds regarding median age at diagnosis, detailed histopathology, clinical effects of imatinib therapy …

us, it (code pays fourni par la source)

We Should Desist Using RECIST, at Least in GIST

Robert S. Benjamin, Haesun Choi, Homer A. Macapinlac, M. A. Burgess et autres

PURPOSE: Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating imatinib-treated gastrointestinal stromal tumors (GISTs). Response by Choi criteria, a 10% decrease in size or a 15% decrease in density on contrast-enhanced CT, correlated well in a small training set …

us (code pays fourni par la source)

Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria

Haesun Choi, C Charnsangavej, Silvana C. Faria, Homer A. Macapinlac et autres

PURPOSE: Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether computed tomography (CT) findings of GIST after imatinib treatment correlate with tumor responses by [18F]fluorodeoxyglucose (FDG) positron emission tomography …

us (code pays fourni par la source)

Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib

Robert H.I. Andtbacka, Chaan S. Ng, Courtney L. Scaife, Janice N. Cormier et autres

us (code pays fourni par la source)

Imatinib resistance in gastrointestinal stromal tumors

Lei L. Chen, Mahyar Sabripour, Robert H.I. Andtbacka, Shreyaskumar Patel et autres

us (code pays fourni par la source)

A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors

Lei L. Chen, Mahyar Sabripour, Elsie F. Wu, Víctor G. Prieto et autres

us (code pays fourni par la source)

A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

Lei L. Chen, Jonathan C. Trent, Elsie F. Wu, Gregory N. Fuller et autres

KIT gain of function mutations play an important role in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of ABL, platelet-derived growth factor receptor (PDGFR), and KIT and represents a new paradigm of targeted therapy against …

us (code pays fourni par la source)